scholarly journals Development and Validation of a Comprehensive Multiparameter-based Scoring System to Assess Pulmonary Fibrosis Severity

2020 ◽  
Author(s):  
Chengsheng Yin ◽  
Yuan Zhang ◽  
Yiliang Su ◽  
Feng Zhang ◽  
Jingyun Shi ◽  
...  

Abstract Background Survival time varies greatly in patients with idiopathic pulmonary fibrosis (IPF). An assessment method that can accurately assess the severity and prognosis of idiopathic pulmonary fibrosis is currently lacking. This study aimed to develop a new method, which can be easily used to assess pulmonary fibrosis severity. Method 1. Development of a HRCT combined pulmonary function & physiological parameter (CTPF) assessment method: The method included two parts. 1) CT-based fibrosis staging: Four representative lung CT sections were selected and evenly divided into 100 small areas. The percentage of honeycomb lesion area in the four sections was determined fibrosis stage,2) PF-based severity grade: FVC%pred,DLco%pred,SpO2% age and gender were used to assess PF severity grade. 2. Validation of the new method: The method was used to assess 192 patients with IPF. Two radiologists used the CT-based fibrosis staging method to determine the fibrosis stage. Pulmonologist determined the PF severity grade. 3. Statistical analyses: Intra-group correlation coefficient to estimate the consistency between the CT scores from the two radiologists. Spearman correlation coefficient to evaluate the correlation between CT scores and lung function parameters. The competitive risk Fine–Gray model was used to analyze the relationship between CT-based stage/PF-based grade and prognosis. CT-based stage, PF-based grade, and GAP stage were used as predictors to predicted the death risk. Results 1. The intra-group correlation coefficient of the CT scores of the two radiologists was 0.95, P<0.05. 2. The CT scores negatively correlated with pulmonary function. 3. The CTPF comprehensive model, showed higher predictive accuracy. Conclusion Combined CT-based staging and PF-based grading methods CTPF can be adopted easily in clinical practice, and can assess IPF severity and predict death risk more accurately.

2020 ◽  
Author(s):  
Chengsheng Yin ◽  
Yuan Zhang ◽  
Yiliang Su ◽  
Feng Zhang ◽  
Jingyun Shi ◽  
...  

Abstract Background: How to accurately assess IPF severity and predict prognosis remains a problem. This study aimed to develop a new method, which can be easily used to assess pulmonary fibrosis severity.Method:1. Development of a HRCT combined pulmonary function & physiological parameter (CTPF) assessment method: The method included two parts. 1) CT-based fibrosis staging: Four representative lung CT sections were selected and evenly divided into 100 small areas. The percentage of honeycomb lesion area in the four sections was determined fibrosis stage,2) PF-based severity grade: FVC%pred,DLco%pred,SpO2% age and gender were used to assess PF severity grade. 2. Validation of the new method: The method was used to assess 192 patients with IPF. Two radiologists used the CT-based fibrosis staging method to determine the fibrosis stage. Pulmonologist determined the PF severity grade. 3. Statistical analyses: By Intra-group correlation coefficient and Spearman correlation coefficient to estimate the consistency between the CT scores from the two radiologists and the correlation between CT scores and lung function parameters. Using the competitive risk Fine–Gray model to analyze the relationship between CT-based stage/PF-based grade and prognosis. CT-based stage, PF-based grade, and GAP stage were used as predictor models to predicted the death risk. Results: 1. The intra-group correlation coefficient of the CT scores of the two radiologists was 0.95, P<0.05. 2. The CT scores negatively correlated with pulmonary function. 3. The CTPF comprehensive model, showed higher predictive accuracy.Conclusion: Combined CT-based staging and PF-based grading methods CTPF can be adopted easily in clinical practice, and can assess IPF severity and predict death risk more accurately.


CHEST Journal ◽  
1997 ◽  
Vol 111 (1) ◽  
pp. 7-8 ◽  
Author(s):  
Steven H. Kirtland ◽  
Richard H. Winterbauer

Immunobiology ◽  
2020 ◽  
Vol 225 (5) ◽  
pp. 151997
Author(s):  
Miriana d’Alessandro ◽  
Laura Bergantini ◽  
Rosa Metella Refini ◽  
Paolo Cameli ◽  
Felice Perillo ◽  
...  

2020 ◽  
Vol 14 (11) ◽  
pp. 997-1007
Author(s):  
Sofia A Moll ◽  
Ivo A Wiertz ◽  
Adriane DM Vorselaars ◽  
Pieter Zanen ◽  
Henk JT Ruven ◽  
...  

Aim: Cancer antigen 15-3 (CA 15-3) is a baseline biomarker in idiopathic pulmonary fibrosis (IPF), but its value during follow-up is unknown. Materials and methods: Associations between serum CA 15-3 and pulmonary function tests during 1-year follow-up were evaluated by a mixed model in 132 IPF treated with pirfenidone or nintedanib. Results: Increased baseline (median: 56 kU/l) and follow-up CA 15-3 levels were inversely associated with forced vital capacity and diffusing capacity of the lung for carbon monoxide (estimates respectively: -5.21 and -4.69; p < 0.001). Baseline and 6-month CA 15-3 above 58.5 (hazard ratio: 1.67; p = 0.031) and 50.5 kU/l (hazard ratio: 2.99; p < 0.001), respectively, showed impaired survival compared with lower levels. Conclusion: CA 15-3 is associated with pulmonary function test during follow-up in IPF on antifibrotic treatment. Higher (follow-up) values are related with poor survival. Therefore, CA 15-3 is a promising follow-up biomarker in IPF.


Sign in / Sign up

Export Citation Format

Share Document